TWST Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.…
Industry Peers
BiotechnologyKey Statistics
About Twist Bioscience (NASDAQ: TWST)
›
Twist Bioscience (NASDAQ: TWST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 111.62 USD on 19 November 2026, up 254.1% over 52 weeks. Its 52-week range is 23.30 USD to 219.71 USD: the price is 49.2% below the high and 379.1% above the low.
Its market capitalisation is 7.61B USD.
Twist Bioscience reports return on equity of -16.4%, an operating margin of -28.8% and revenue up 27.9% year over year.
It holds more cash than debt, a net cash position of 471.92M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 128.92 USD is 15.5% above the current price.